PRCT PROCEPT BioRobotics Corporation
USHealthcareAs of 2026-07-10 16:00
Why PRCT matters now
PROCEPT BioRobotics Corporation (PRCT) is a US stock in Healthcare. The latest InvestLog snapshot shows $20.89 with +5.77% on the session and $1.19B in market capitalization; recent performance reads 1-month -16.17% and YTD -30.96%.
The latest financial table shown here is Q1 2026, with revenue of $83.1M, net income of $-31.6M, and EPS of $-0.56. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -6.5%.
The latest indexable market news headline is "Here Are Thursday’s Best Wall Street Analyst Research Calls: Callaway Golf, Chewy, CME Group, Danaher, General Dynamics, Intel, SpaceX, Rocket Lab, Toast, and More" from 247 Wallst.
Additional event context on this page matters because analyst consensus is Hold with a median target of $32.00; recent insider activity includes PUCKETT DAN filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
3.53
P/S
3.84
EV/EBITDA
-11.32
DCF Value
$52.44
FCF Yield
-6.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
63.0%
Operating Margin
-33.9%
Net Margin
-31.8%
ROE
-27.7%
ROA
-21.0%
ROIC
-25.7%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $83.1M | $-31.6M | $-0.56 |
| Q4 2025 | $76.4M | $-29.8M | $-0.53 |
| FY 2025 | $308.1M | $-95.6M | $-1.72 |
| Q3 2025 | $83.3M | $-21.4M | $-0.38 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$32.00
Target (Median)
$32.00
Target Range
$29.00 - $35.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Devices
Country
US
Exchange
—
Beta
0.85
PROCEPT BioRobotics Corporation specializes in pioneering surgical robotic technologies, offering innovative solutions within the field of urology. Its flagship product is the AquaBeam Robotic System, a sophisticated, image-guided surgical robot designed for minimally invasive urological procedures. This system primarily facilitates Aquablation therapy, which the company also devised, to alleviate lower urinary tract symptoms in male patients diagnosed with benign prostatic hyperplasia (BPH). As of year-end 2021, PROCEPT BioRobotics had successfully deployed 130 AquaBeam Robotic Systems across the globe, with a significant majority—78 units—located in the United States. Founded in 2007, the corporation maintains its headquarters in Redwood City, California.